Form 8-K - Current report:
SEC Accession No. 0001558370-25-002912
Filing Date
2025-03-13
Accepted
2025-03-13 17:00:16
Documents
14
Period of Report
2025-03-11
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avbp-20250311x8k.htm   iXBRL 8-K 43047
2 EX-16.1 avbp-20250311xex16d1.htm EX-16.1 3532
  Complete submission text file 0001558370-25-002912.txt   173707

Data Files

Seq Description Document Type Size
3 EX-101.SCH avbp-20250311.xsd EX-101.SCH 3408
4 EX-101.LAB avbp-20250311_lab.xml EX-101.LAB 16578
5 EX-101.PRE avbp-20250311_pre.xml EX-101.PRE 10711
16 EXTRACTED XBRL INSTANCE DOCUMENT avbp-20250311x8k_htm.xml XML 5051
Mailing Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269
Business Address 18 CAMPUS BLVD. SUITE 100 NEWTOWN SQUARE PA 19073-3269 240-780-6356
ArriVent BioPharma, Inc. (Filer) CIK: 0001868279 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41929 | Film No.: 25736665
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)